Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS
Contenuto archiviato il 2024-04-30

Human chemokines and their receptors: genomic organization of the gene families, functional characterization of their members and relevance to human diseases

Obiettivo



Chemokines are small-secreted proteins that recruit white blood cells to the sites of inflammation. They play a fundamental role in the host defence against infection by viruses, bacteria and parasites. The protective effects of chemokines can however turn harmful to healthy tissues when their expression is inadequate. Chemokines contribute therefore to the damage in a wide range of acute and chronic inflammatory diseases. Chemokines have also been involved in number of other physiological and pathological processes. MCP-1 contributes to the development of artery-blocking plaques in atherosclerosis. Several chemokinare involved in cancer, either as growth factor GRO alpha), or as agents promotineo angiogenesis (IL-8). Others, such as PF-4, have potent angiostatic properties, and are considered as potential anticancer agents. MIP-1alpha, amon others, regulates differentiation, mobilization and proliferation of bone arrow stem cells. Recently, MIP-1alpha, MIP-1beta and RANTES have been identified as the major HIV-suppressive factors produced by CD8+ lymphocytes, and two chemokine receptors (an orphan receptor termed fusin, and CC-CKR5) were shown constitute the accessory factors (in addition to CD4) required for HIV-1 fusion with its host cells. This array of biological functions makes of chemokines and their Gprotein-couple receptors important targets for the pharmaceutical industry, in various therapeutic areas. Importantly, the range of actions of individual chemokines, and the cell distribution of their receptors, is relatively specific, as compared to other cytokine and cytokine receptor families.

Therapeutic agents acting on restricted cell populations can therefore be considered. Nevertheless, much has still to be done to apprehend chemokine signaling as a whole. Over 25 chemokines, and more than a dozen chemokine orputative chemokine receptors have been described, but relatively few links have been made so far between ligands and receptors. This suggests that many remembers, in each gene family, are still to be discovered, an hypothesis largely supported by the results of recent experiments aiming at identifying new molecules. Chemokine and chemokine receptor genes are known to be clustered in the human genome. Taking advantage of this clustering, the aim of the program is to study the ligand and receptor families using an integrated and targeted approach at the genomic level.

The program will specifically:
1) establish precise physical and sequence ready maps of the chemokine and chemokine receptor clusters of the human genome;
2) identify novel members of both families by polymerase chain reaction and shotgun sequencing of BACs;
3) produce recombinant proteins from the newly identified genes, and investigate which chemokines are active on which receptors;
4) determine the cell-type, and/or stimulus-dependent regulation of the genes expression;
5) delineate the array of biological activities of the novel chemokines, by in vitro and in vivo assays; 6)investigate the involvement of novel chemokines and receptors in a variety of human diseases, with a special emphasis on chronic inflammatory diseases and AIDS. Recently discovered chemokines and receptors will be included in this study as well.

This multidisciplinary program will bring together leading laboratories in their respective areas and a European biotechnology company. The expertise of the partners is highly complementary. The research is expected to bring into light new chemokines and receptors that will constitute novel targets for drug discovery. This program and its subsequent developments will therefore contribute to improve the competitiveness of the European biotechnology and pharmaceutical industries.

Campo scientifico (EuroSciVoc)

CORDIS classifica i progetti con EuroSciVoc, una tassonomia multilingue dei campi scientifici, attraverso un processo semi-automatico basato su tecniche NLP. Cfr.: Il Vocabolario Scientifico Europeo.

È necessario effettuare l’accesso o registrarsi per utilizzare questa funzione

Programma(i)

Programmi di finanziamento pluriennali che definiscono le priorità dell’UE in materia di ricerca e innovazione.

Argomento(i)

Gli inviti a presentare proposte sono suddivisi per argomenti. Un argomento definisce un’area o un tema specifico per il quale i candidati possono presentare proposte. La descrizione di un argomento comprende il suo ambito specifico e l’impatto previsto del progetto finanziato.

Invito a presentare proposte

Procedura per invitare i candidati a presentare proposte di progetti, con l’obiettivo di ricevere finanziamenti dall’UE.

Dati non disponibili

Meccanismo di finanziamento

Meccanismo di finanziamento (o «Tipo di azione») all’interno di un programma con caratteristiche comuni. Specifica: l’ambito di ciò che viene finanziato; il tasso di rimborso; i criteri di valutazione specifici per qualificarsi per il finanziamento; l’uso di forme semplificate di costi come gli importi forfettari.

CSC - Cost-sharing contracts

Coordinatore

UNIVERSITE LIBRE DE BRUXELLES
Contributo UE
Nessun dato
Indirizzo
808,Route de Lennik 808 Campus Erasme - Building C
1070 BRUXELLES
Belgio

Mostra sulla mappa

Costo totale

I costi totali sostenuti dall’organizzazione per partecipare al progetto, compresi i costi diretti e indiretti. Questo importo è un sottoinsieme del bilancio complessivo del progetto.

Nessun dato

Partecipanti (3)

Il mio fascicolo 0 0